UBS Global Biopharma Conference 2026
Logotype for Kodiak Sciences Inc

Kodiak Sciences (KOD) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Kodiak Sciences Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

Tarcocimab efficacy and filing

  • DAYBREAK showed tarcocimab’s vision and fluid-control immediacy at least comparable to EYLEA; after four loading doses, over half of patients reached six-month dosing under stringent retreatment criteria.

  • Dosing was capped at six months, yet most patients did not meet retreatment criteria by that point; human half-life averaged 20 days, ranging from 10 to 50 days.

  • A revised formulation combining free and conjugated antibody was credited with supporting the results.

  • The BLA is being compiled across wet AMD, diabetic retinopathy and retinal vein occlusion, with filing targeted this year and potential approval in 2027.

  • Management cited an anti-VEGF market of about $15B; EYLEA HD was described as exceeding $8B and Vabysmo as trending above $5B, with expectations of $7B-$8B.

KSI-101 and MESI opportunity

  • MESI is macular edema associated with ocular inflammation; management estimated an initial U.S. addressable population of ~150,000 and described KSI-101 as a VEGF/IL-6 bispecific.

  • Phase III PEAK tests 5 mg and 10 mg against sham in severely affected cohorts; six monthly loading doses precede the week-24 endpoint, with mean vision change and 15-letter gain among key measures.

  • First top-line data are expected before Christmas; management expressed confidence and hopes for mean vision gains above 10 letters, while citing prior phase I/II responder rates above 50% in the sicker-patient group.

  • The second pivotal is almost fully enrolled, with completion expected this year and data targeted for May/June; a BLA is planned if development supports filing.

  • Management highlighted immediate fluid control in earlier studies and sees potential across MESI’s diverse inflammatory causes; it contrasted the program with Roche’s narrower anti-IL-6 approach and mixed phase III results.

Pipeline, commercial readiness and financing

  • KSI-501 had a positive DAYBREAK result in wet AMD and is being evaluated in phase III ALTO, where enrollment and randomization are progressing.

  • Antibodies are made in the U.S. and conjugates in Switzerland at a co-owned, dedicated facility; management said the facility can provide required commercial supply and is Swissmedic approved.

  • Management is building commercial capability for retina medicines, citing buy-and-bill potential, attractive pricing and an agile model for a focused U.S. specialty market.

  • A $70M ATM offering was completed recently; after the PEAK readout, management is considering a traditional financing intended to fund roughly the next 18 months, while emphasizing measured fundraising.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kodiak Sciences